Peritoneal mesothelioma

Current Treatment Options in Oncology

Volumn 9, Issue 2-3, 2008, Pages 180-190

  Hesdorffer, Mary E ^a   Chabot, John ^b   DeRosa, Carolyn ^b   Taub, Robert ^a  

^a Mesothelioma Applied Research Foundation   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CRS 207; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IMMUNOTOXIN; MITOMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MORAB 009; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PYRIDOXINE; TAXALOG; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VORINOSTAT;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CREATININE CLEARANCE; CYTOREDUCTIVE SURGERY; DIET THERAPY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; EDEMA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEARING LOSS; HUMAN; ILEUS; LAPAROTOMY; LEUKOPENIA; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERITONEUM MESOTHELIOMA; POSTOPERATIVE COMPLICATION; PROGNOSIS; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; WEAKNESS;

AGED; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 58149092611     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0072-2     Document Type: Article

References (48)

1. Price B. Analysis of current trends in united states mesothelioma incidence. Am J Epidemiol. 1997;145(3):211-218.
2. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases. Thorax. 1997;52(6):507-512.
3. Cocco P, Dosemeci M. Peritoneal cancer and occupational exposure to asbestos: Results from the application of a job-exposure matrix. Am J Ind Med. 1999;35(1):9-14. doi:10.1002/ (SICI)1097-0274(199901)35:1<9::AID-AJIM2>3.0.CO;2-V
4. Browne K, Smither WJ. Asbestos-related mesothelioma: Factors discriminating between pleural and peritoneal sites. Br J Ind Med. 1983;40(2):145-52.
5. Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008;14(4):316-321. doi: 10.1097/MCP.0b013e3283018220
6. Matanoski GM, Tonascia JA, Correa-Villasenor A, Yates KC, Fink N, Elliott E, et al.: Cancer risks and low-level radiation in U.S. shipyard workers. J Radiat Res (Tokyo) 2008, 49(1):83-91. doi: 10.1269/jrr.06082
7. Gentiloni N, Febbraro S, Barone C, Lemmo G, Neri G, Zannoni G, et al. Peritoneal mesothelioma in recurrent familial peritonitis. J Clin Gastroenterol 1997;24(4):276-279. doi: 10.1097/00004836-199706000-00023
8. Elias D, Bedard V, Bouzid T, Duvillard P, Kohneh-Sharhi N, Raynard B, et al. Malignant peritoneal mesothelioma: Treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31(10):784-788. doi: 10.1016/S0399-8320(07)73964-7
9. Nonaka D, Kusamura S, Baratti D, Casali P, Cabras AD, Younan R, et al. Diffuse malignant mesothelioma of the peritoneum: A clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104(10):2181-2188. doi: 10.1002/cncr.21239
10. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560-7. doi: 10.1200/JCO.2003.04.150
11. Vogelzang NJ. Emerging insights into the biology and therapy of malignant mesothelioma. Semin Oncol. 2002;29(6 Suppl 18):35-42. doi: 10.1016/S0093-7754(02)70044-4
12. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: A study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol. 2005;123(5):724-37. doi: 10.1309/2H0NVRERPP2LJDUA
13. Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004;17(4):476-481. doi: 10.1038/ modpathol.3800067
14. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol. 1977; 8(1):83-94. doi: 10.1016/S0046-8177(77)80067-1
15. Sebbag G, Sugarbaker PH. Peritoneal mesothelioma proposal for a staging system. Eur J Surg Oncol. 2001;27(3):223-4. doi: 10.1053/ejso.2001.1044
16. Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, et al. Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET. Radiographics. 2004;24(1):105-119. doi: 10.1148/rg.241035058
17. Busch JM, Kruskal JB, Wu B.: Armed Forces Institute of Pathology. Best cases from the AFIP malignant peritoneal mesothelioma. Radiographics 2002, 22(6):1511-1515. doi: 10.1148/rg.226025125
18. Rusch VW, Godwin JD, Shuman WP. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1988;96(1):171-177.
19. Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al.: Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006, 13(2):229-237. doi: 10.1245/ASO.2006.03.045
20. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al.: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008, 85(1):265, 272; discussion 272
21. Vogelzang NJ. Malignant mesothelioma: Diagnostic and management strategies for 1992. Semin Oncol. 1992;194(Suppl 11):64-71.
22. Markman M, Cleary S, Pfeifle C, Howell SB. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer. 1986;58(1):18-21. doi:10.1002/ 1097-0142(19860701)58:1<18::AID-CNCR2820580105>3.0.CO;2-C
23. Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008; 31(1):49-54.
24. Sugarbaker PH. Local-regional approach to diffuse malignant peritoneal mesothelioma. Gastroenterol Clin Biol. 2007;31(10):780-781. doi: 10.1016/ S0399-8320(07)73963-5
25. Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93-6. doi: 10.1002/jso.20676
26. Lomas DA, Wallis PJ, Stockley RA. Palliation of malignant ascites with a tenckhoff catheter. Thorax. 1989;44(10):828.
27. Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH. Long-term survival in peritoneal mesothelioma the role of radiotherapy and combined modality treatment. Cancer 1987;59(11):1882-6. doi:10.1002/ 1097-0142(19870601)59:11<1882::AID-CNCR2820591107>3.0.CO;2-0
28. Takeuchi K, Fujimoto M, Tsujino T, Takeda Y, Yoshida S. Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel. Eur J Gynaecol Oncol 2007;28(4):322-3.
29. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005; 16(6):923-7. doi: 10.1093/annonc/mdi187
30. Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40-46.
31. Nowak AK, Byrne MJ. Cisplatin and gemcitabine in malignant mesothelioma. Ann Oncol. 2005;16(10):1711. doi: 10.1093/annonc/mdi303
32. Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study. Cancer. 2003;97(11):2791-7. doi: 10.1002/cncr.11405
33. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer. 2008;99(1):44-50. doi: 10.1038/sj.bjc.6604421
34. Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma - a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007 Feb;14(2):515-525. doi: 10.1245/s10434-006-9187-5
35. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: Results of a prospective study. Ann Surg Oncol. 2006;13(3):405-412. doi: 10.1245/ASO.2006.05.041
36. Costamagna D, Scuderi S, Vaira M, Barone R, De Simone M. Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy. Tumori. 2003;89(4 Suppl):40-2.
37. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, et al.: Preclinical evaluation of MORAb-009 a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007, 7:20.
38. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13(17):5144-9. doi: 10.1158/1078-0432.CCR-07-0869
39. Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemother Pharmacol 2007;60(2):203-9. doi: 10.1007/ s00280-006-0362-y
40. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7(4):257-261.
41. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: High rate of antitumor immune responses. Clin Cancer Res. 2007;13(15 Pt 1):4456-66. doi: 10.1158/1078-0432.CCR-07-0403
42. Vachani A, Sterman DH, Albelda SM. Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol. 2007;2(4):265-7. doi: 10.1097/ 01.JTO.0000283041.12165.54
43. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ ganciclovir suicide gene therapy. Clin Cancer Res. 2005;11(20):7444-53. doi: 10.1158/1078-0432.CCR-05-0405
44. Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett. 2008;265(1):55-66. doi: 10.1016/j.canlet.2008.02.018
45. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med. 2008;14(4):303-9. doi: 10.1097/MCP.0b013e328302851d
46. Palumbo C, Bei R, Procopio A, Modesti A. Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem. 2008;15(9):855-67. doi: 10.2174/092986708783955446
47. Porret E, Madelaine J, Galateau-Salle F, Bergot E, Zalcman G. Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update. Rev Mal Respir 2007;24(8 Pt 2):6S157-64.
48. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008;5(3):136-47. doi: 10.1038/ncponc1039